Chimera Bioengineering Overview
- Founded
-
2015
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$7.5M
- Investors
-
13
Chimera Bioengineering General Information
Description
Developer of gene therapeutics designed to re-program the immune system and treat cancer. The company's therapeutics are immune cells hot-wired to circumvent immune evasion and redirect them to find and kill tumor cells that are decorated with a defined target antigen, enabling unresponsive patients to recover against solid tumor cancer and life-threatening toxicities.
Contact Information
Website
www.chimera.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 329 Oyster Point Boulevard
- 3rd Floor
- South San Francisco, CA 94080
- United States
+1 (310) 000-0000
Chimera Bioengineering Timeline
Chimera Bioengineering Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Grant | 28-Apr-2022 | $7.5M | 000.00 | Completed | Generating Revenue | |
| 5. Later Stage VC (Series A) | 09-Feb-2022 | 000.00 | 000.00 | 000.00 | Completed | Generating Revenue |
| 4. Debt - General | 31-Mar-2020 | 00000 | Completed | Generating Revenue | ||
| 3. Accelerator/Incubator | 26-Jul-2017 | 00000 | 00000 | Completed | Pre-Clinical Trials | |
| 2. Accelerator/Incubator | 01-Jul-2017 | Completed | Pre-Clinical Trials | |||
| 1. Accelerator/Incubator | 03-Mar-2015 | Completed | Pre-Clinical Trials |
Chimera Bioengineering Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-4 | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A-3 | 000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
| Series A-2 | 7,000,000 | $0.001000 | $0.02 | $0.27 | $0.27 | 1x | $0.27 | 9.38% |
| Series A-1 | 24,000,000 | $0.001000 | $0.02 | $0.33 | $0.33 | 1x | $0.33 | 32.15% |
Chimera Bioengineering Executive Team (5)
Chimera Bioengineering Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Benjamin Wang Ph.D | Chimera Bioengineering | Co-Founder, Chief Operating Officer & Board Member | 000 0000 |
| Catherine Thodey | Chimera Bioengineering | Board Member | 000 0000 |
| Gusti Zeiner Ph.D | Chimera Bioengineering | Co-Founder, Chief Science Officer & Board Member | 000 0000 |
| Ram Shriram | Chimera Bioengineering | Board Member | 000 0000 |
| Scott Dylla Ph.D | Self | Chairman | 000 0000 |
Chimera Bioengineering Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Chimera Bioengineering Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| AFCR | Other | 000 0000 | 000000 0 | ||
| AIM-HI | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
| Band of Angels | Angel Group | Minority | 000 0000 | 000000 0 | |
| Founders Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Kairos Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |